Government healthcare officials in Canada have published a recent review considering the possible link between Levaquin, Avelox, and related fluoroquinolone antibiotics and retinal detachment. Retinal detachment occurs when the retina of the eye peels away from the surrounding tissue. If left untreated the retina may completely detach, causing blindness or other permanent vision problems.
The safety review conducted by Health Canada has been ongoing since reports began surfacing three years ago in the Journal of the American Medical Association (JAMA), which published a study that one in thirty patients diagnosed with retinal detachment had taken Levaquin, Cipro, Avelox, or another fluoroquinolone. The use of fluoroquinolone antibiotics had already been identified as a cause of connective tissue related injuries, including tendon damage.
“Health Canada’s follow-up safety review concluded that a potential link between the use of oral fluoroquinolones and retinal detachment could not be ruled out at this time,” the summary states. “Given that retinal detachment is a medical emergency, the recommendations of the Health Canada review were that the current labeling for oral fluoroquinolones be revised to highlight the urgency to consult a health care professional if patients experienced vision problems during or following oral fluoroquinolone’s administration.”
Investigators looked into 26 studies considering retinal detachment and the use of fluoroquinolones when making their determination. The findings of Health Canada do not impact regulatory requirements for fluoroquinolones in the United States.
If you or a loved one have taken fluoroquinolones such as, Levaquin, Cipro, and Avelox and suffered connective tissue injuries such as Achilles tendon rupture or retinal detachment, or neurological injury such as peripheral neuropathy you may be eligible for compensation. Please fill out the contact form on this page, call Arentz Law Group at 1-800-305-6000, or text 800-440-4400 to begin a free review of your claim.